This comprehensive and critical review of current and established
treatment modalities for malignant liver tumors is designed to help
you sort through the proliferation of competitive approaches and
choose the best treatment options for your patient. Dr. Clavien and
his contributors consider all the options – radiological,
surgical, pharmaceutical, and emerging/novel therapies – and
help you find the best single or combined therapy.
Building on the success of the previous edition, this extremely
thorough revision:
* features a new section on Guidelines for Liver Tumors, where
you will find specific strategies for treating common liver
malignancies; the guidelines were prepared by the Associate Editors
and take into account national and international society
guidelines
* reflects actual practice by taking a multidisciplinary
approach, with contributions from international experts who have
extensive experience with this patient population
* achieves comprehensive and balanced coverage by having each
chapter reviewed by the Editor, Deputy Editor, two Associate
Editors, and at least one external reviewer
* includes 16 new chapters that cover liver anatomy, histologic
changes in the liver, epidemiology and natural history of HCC, CCC
and colorectal liver metastases, strategies of liver resection, and
economic aspects as well as novel therapies
* facilitates the kind of daily interaction among hepatologists,
hepatic surgeons, medical oncologists, radiotherapists, and
interventional radiologists that is essential when treating
patients with complex liver malignancies
In 44 chapters organized into six major sections, the book
covers the full range of liver tumors. The perfect blend of
evidence and experience, Malignant Liver Tumors: Current and
Emerging Therapies, 3rd Edition, illuminates the
path to better patient care.
Om författaren
Editor-in-Chief:
Pierre-Alain Clavien
Department of Visceral and Transplant Surgery, University Hospital
Zurich, Switzerland
Associate Editors:
Tadatoshi Takayama, Second Department of Surgery, Faculty of
Medicine, University of Tokyo, Japan
CM Lo, Liver Transplant Centre, Queen Mary Hospital, 102
Pokfulam Road, Hong Kong
R. Chari, Associate Professor of Surgery and Cancer
Biology, Division Chief of Hepatobillary Surgery and Liver
Transplantation, Staff Surgeon, Veterans Affairs Medical Center,
Vanderbilt University Medical Center, Nashville, USA
M. Morse, Associate Professor, Duke University Medical
School, Durham, USA
J. Llovet, Barcelona-Clínic Liver Cancer Group,
Liver Unit, Institut d’Investigacions Biomédiques August Pi I
Sunyer, Hospital Clínic, University of Barcelona, Catalonia,
Spain